757 Different patterns of disability, cognitive function and quality of life in 1065 elderly heart failure patients treated or not with betablockers: the BRING‐UP2 study

criteria of MADIT II trial at the moment of their first visit. Finally, a total of 81 patients were selected. The mean of age was 64 ± 9 years old, 86% were males and 67% were in NYHA functional class >= II. The mean of follow-up period was 19 months (range: 1 to 48 months). There were 8 deaths (9,8%), 4 sudden deaths, 3 due to advanced heart failure and 1 due to non cardiac cause. Three years cumulated survival in our series was 81% compared with 69% in conventional group and 78% in the defibrillator group in MADIT II trial. Percentage of patients taking ACE inhibitors was 84%, betablockers 85%, espironolactone 43%, statins 79% and amiodarone 4%. Prophylactic implantation of a desfibrillator to all 81 patients in our series would have avoided between 2 and 3 deaths at a mean follow-up period of 19 months, according to MADIT II trial results. Conclusions: appropriate use of pharmacologic treatment in patients like MADIT II trial, managed in an specialized program of heart failure, can reduce the mortality of this group of patients until a level in which the prophylactic implantation of a defibrillator without additional risk stratification would be, at least, questionable in terms of cost effectiveness.